These clinically measured features of disease included markers of kidney injury (incident acute kidney injury, development of end-stage renal disease, creatinine and BUN blood levels), markers of liver injury (liver transaminases AST and ALT), cell counts (neutrophils, lymphocytes, monocytes, platelets), levels of d-dimer, ferritin, lactate and lactate dehydrogenase (LDH). This evidence concerns the gene GPT and chronic kidney disease.